opthalmology
Mundipharma expands ophthalmology portfolio in Latin America with commercial partnership
Mundipharma has expanded its ophthalmology portfolio in Latin America through a new commercial partnership agreement with Italian pharmaceutical company, NTC. more
Birmingham scientists go one step further in developing potential topical AMD treatment
Scientists from the University of Birmingham have taken a further step in their research, developing an eye drop that could be a paradigm shift in the treatment arsenal for age-related macular degeneration (AMD). more
Agreement formed for development of AAV vectors for ocular gene therapy
German-based company, SIRION Biotech has signed a two-year development agreement with a clinical-stage ophthalmology company, Acucela, to establish optimised adeno associated virus (AAV) vectors for clinical applications in ocular gene therapy. more
NTC and Santen partner on fixed combination ophthalmic therapeutic solution
Italian pharmaceutical company, NTC, has entered into a commercial partnership with Santen Pharmaceutical — a pharma company focused on ophthalmology. more
NTC grants licence and distribution rights of ophthalmic products to Mundipharma
Italian pharmaceutical company, NTC, has granted licence and distribution rights of a portfolio of ophthalmic products to Mundipharma — a pharmaceutical company with a presence in ophthalmology. more
Shire submits marketing authorisation application for dry eye treatment
Global biotechnology company, Shire, has submitted a marketing authorisation application (MAA) for its dry eye treatment, liftegrast, which, if approved, would represent the first and only LFA-1 antagonist drug to treat the disease in Europe. more
Eyeing up adherence: A recent partnership addresses the challenges in clinical trials
A recent partnership to address the challenge of monitoring adherence in ophthalmic clinical trials was formed between Aptar Pharma and Kali Care. Here, Sina Fateh and Sai Shankar discuss this alliance further. more
Elasmogen receives grant and equity investment
Elasmogen, developer of soloMER biologics, has announced receipt of a Biomedical Catalyst Grant to support development of next generation ophthalmology biologics. more
Implandata announces successful implantation of micro-sensor for intraocular pressure measurement in glaucoma patient
After implantation of the micro sensor the patient’s intraocular pressure measurements can be measured at any chosen frequency. more
Santen closes asset purchase agreement regarding acquisition of ophtalmology assets from Merck
The completed transaction concerns products primarily intended for Asia, including Japan, South Korea and Europe excluding some countries more
